CONTRAVE
Peaknaltrexone hydrochloride and bupropion hydrochloride
NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the…
Clinical Trials (3)
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
Started Jul 2024
40 enrolled
ObesityWeight LossWeight Management+2 more
A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery
Started Apr 2021
18 enrolled
Obesity
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
Started Feb 2021
89 enrolled
Obesity
Loss of Exclusivity
LOE Date
Jul 2, 2034
101 months away
Patent Expiry
Jul 2, 2034